Product information and disease descriptionProduct descriptionProduct information
Special populations
2 evidence topics · 2 sources
Summary
The Chinese prescribing information states that older adults do not require a dose adjustment.
Ivonescimab
EGFR-mutated non-small-cell lung cancer
- Manufacturer
- Summit Therapeutics
- Regulatory submission
- BLA submitted in the fourth quarter of 2025
- Launch
- Not announced
- Last updated